Grace Therapeutics (GRCE) Intangibles (2017 - 2026)
Grace Therapeutics (GRCE) posted Intangibles of $41.1 million for Q1 2026, little changed sequentially from $41.1 million in Q4 2025, and little changed YoY from $41.1 million in Q1 2025.
Grace Therapeutics (GRCE) Intangibles (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Intangibles for 10 years, with the latest figure at $41.1 million in Q1 2026.
- Quarterly Intangibles changed 0.0% year-over-year to $41.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.1 million (changed 0.0% YoY) and the FY2026 annual result came in at $41.1 million, changed 0.0% from the prior year.
- Intangibles steadied at $41.1 million in Q1 2026 per GRCE's latest filing, from $41.1 million in the prior quarter.
- Over five years, Intangibles peaked at $69.8 million in Q1 2022 and troughed at $4.3 million in Q1 2023.
- A 5-year average of $41.1 million and a median of $41.1 million in 2023 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2025: Intangibles plunged 93.79% in 2023, then jumped 848.31% in 2025.
- Over 5 years, Intangibles stood at $69.8 million in 2022, then tumbled by 41.09% to $41.1 million in 2023, then changed by 0.0% to $41.1 million in 2024, then changed by 0.0% to $41.1 million in 2025, then changed by 0.0% to $41.1 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $41.1 million, $41.1 million, and $41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Grace Therapeutics | 37.82 Mn | 37.82 Mn | - | 27.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.60 Mn |
| Mar 31, 2026 | 41.13 Mn |
| Dec 31, 2025 | 41.13 Mn |
| Sep 30, 2025 | 41.13 Mn |
| Jun 30, 2025 | 41.13 Mn |
| Mar 31, 2025 | 41.13 Mn |
| Dec 31, 2024 | 41.13 Mn |
| Sep 30, 2024 | 41.13 Mn |
| Jun 30, 2024 | 41.13 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Dec 31, 2023 | 41.13 Mn |
| Sep 30, 2023 | 41.13 Mn |
| Jun 30, 2023 | 41.13 Mn |
| Mar 31, 2023 | 4.34 Mn |
| Dec 31, 2022 | 69.81 Mn |
| Sep 30, 2022 | 27.60 Mn |
| Jun 30, 2022 | 69.81 Mn |
| Mar 31, 2022 | 69.81 Mn |
| Dec 31, 2021 | 65.21 Mn |
| Sep 30, 2021 | 65.21 Mn |